pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Rybrevant
drug
save

amivantamab

Marketedupdated 6mo ago
by Janssen Biotech Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval52 co-mentions · 13 sources
  • drugRYBREVANT48 co-mentions · 13 sources
  • companyJanssen Biotech Inc26 co-mentions · 13 sources
  • drugRYBREVANT FASPRO8 co-mentions · 2 sources
  • drug(amivantamab + hyaluronidase (human recombinant))4 co-mentions · 2 sources

indications

investigational
NSCLC

all catalysts(11)

approval · 11
May 21, 2021
approval
6y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Dec 21, 2021
approval
5y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 4, 2022
approval
4y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Mar 1, 2024
approval
3y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Aug 19, 2024
approval
2y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Sep 19, 2024
approval
2y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Feb 14, 2025
approval
2y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Aug 14, 2025
approval
1y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Sep 3, 2025
approval
1y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Oct 8, 2025
approval
1y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 7, 2025
approval
1y ago
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
view all 11 catalysts →

Trials studying amivantamab

  • phase1A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumorsrecruitingn=400
  • phase2A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancerrecruitingn=520
  • phase1A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Canceractive not recruitingn=701
  • phase3A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Canceractive not recruitingn=418
  • phase3A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertionsactive not recruitingn=308
  • phase2Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancerenrolling by invitationn=50
  • phase3A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failureactive not recruitingn=776
  • phase3A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapyrecruitingn=700

News(10)

  • J&J’s Rybrevant nets FDA approval in head and neck cancer
    The FDA has granted accelerated approval to Johnson & Johnson’s cancer shot Rybrevant in head and neck cancer that’s come back after previous chemotherapy and immunotherapy. The approval is the fir…
    endpoints · 12d ago
  • FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
    The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and n…
    fda_press · 13d ago
  • ArriVent collapses on disappointing lung cancer data
    More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.
    biopharma_dive · 1mo ago
  • ArriVent’s phase 3 lung cancer trial flops, sinking stock
    A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading on the Nasdaq.
    fiercebiotech · 1mo ago
  • Rare EGFR mutation increases lung cancer risk 62 times in never smokers
    A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.
    fiercebiotech · 2mo ago
  • Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
    Analysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is alread…
    biospace · 2mo ago
  • Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
    Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…
    fiercebiotech · 2mo ago
  • New Taiho, Cullinan data heats up lung cancer drug battle
    The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
    biopharma_dive · 3mo ago
  • Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
    Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
    biospace · 3mo ago
  • Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
    Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…
    endpoints · 3mo ago
view all news mentions →
brand
Rybrevant
generic
amivantamab-vmjw
indication
Non-Small Cell Lung Cancer
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?